Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 1447-1455 | ISSN:2251-6727

Ephedrine and Pseudoephedrine: A Comprehensive Review of Their Pharmacology and Clinical Applications

Pawan Mandal[1], Amandeep Singh[2], Krishika Sharma[3], Pragati Jain[4], Manisha[5], Manvi Chaudhary[6], Pragna Chinmayee[7], Poorvi Ujjainia[8]

[1]Assistant Professor, Department of Forensic Science, RIMT University, Mandi Gobindhgarh, Punjab, India

[2]Postgraduate, Institute of Biotechnology, Chandigarh University, Mohali, Punjab, India

[3]Postgraduate, Institute of Microbiology, Guru Nanak Dev University, Amritsar, Punjab, India

[4,5,7,8]Postgraduate, Department of Forensic Science, Chandigarh University, Mohali, Punjab, India

[6]Lecturer, Department of Forensic Science, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh,India

(Received: 27 October 2023 Revised: 22 November Accepted: 26 December)

KEYWORDS

Ephedrine, Pseudoephedrine, Forensic Science, Sympathomimetic amines, Decongestants, Bronchodilators, Toxicology, Pharmacokinetics;

ABSTRACT:

Ephedrine and pseudoephedrine are both sympathomimetic amines with a wide range of pharmacological effects on the cardiovascular, respiratory, and central nervous systems. In this comprehensive review, we explore the pharmacology and clinical applications of these two compounds, with a focus on their use as decongestants and bronchodilators.We begin by describing the molecular structure and mechanisms of action of ephedrine and pseudoephedrine, including their effects on adrenergic receptors and the release of endogenous catecholamines. We then review the pharmacokinetics of these compounds, including their absorption, distribution, metabolism, and excretion.Next, we discuss the clinical uses of ephedrine and pseudoephedrine, focusing on their effectiveness as decongestants for nasal and sinus congestion and as bronchodilators for asthma and other respiratory conditions. We also examine their potential use in the treatment of hypotension, narcolepsy, and obesity.Finally, we discuss the safety and potential adverse effects of ephedrine and pseudoephedrine, including their potential for abuse and dependence, cardiovascular effects, and interactions with other medications. We conclude with recommendations for the appropriate use of these compounds in clinical practice, including dosage recommendations and monitoring for potential adverse effects.

1. Introduction

Ephedrine and pseudoephedrine are two alkaloids that have been widely used in the field of medicine for their bronchodilatory and decongestant effects [1]. These two compounds are structurally similar and have a shared mechanism of action, but they differ in terms of their pharmacological properties and clinical applications [2].

Ephedrine, also known as ma-huang, is derived from the plant Ephedra sinica and has been used for centuries in traditional Chinese medicine[3]. In modern medicine, ephedrine is primarily used as a bronchodilator to treat asthma and as a vasoconstrictor to manage hypotension and shock. Ephedrine can also stimulate the central nervous system, which makes it useful in the treatment of narcolepsy and depression [4].Pseudoephedrine, on the other hand, is a synthetic compound that is structurally similar to ephedrine. Pseudoephedrine is commonly used as a decongestant to relieve symptoms of nasal congestion caused by allergies, colds, or sinusitis. Pseudoephedrine acts by reducing the swelling of the nasal passages, which allows for easier breathing [5].Despite their therapeutic benefits, ephedrine and pseudoephedrine are also known to have potential adverse effects. Ephedrine can cause hypertension, tachycardia, and arrhythmias, while pseudoephedrine

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 1447-1455 | ISSN:2251-6727

can cause nervousness, restlessness, and insomnia [6]. Both compounds are also known to have abuse potential and have been banned or regulated in many countries due to their use in the production of methamphetamine [7].Given their complex pharmacological profile, it is important for healthcare professionals to have a comprehensive understanding of ephedrine and pseudoephedrine, including their mechanism of action, therapeutic applications, and potential risks [8]. This review aims to provide a thorough overview of the pharmacology and clinical applications of ephedrine and pseudoephedrine, as well as their associated adverse effects and regulatory status.

1.1 Molecular Structure

Ephedrine and Pseudoephedrine are both alkaloids that are commonly used as decongestants and bronchodilators [9].

In **Fig.1**. , the central carbon atom (C) is bonded to an amino group (N), a hydroxyl group (OH), and two methyl groups (CH3). The nitrogen atom is also bonded to a hydrogen atom (H). The two methyl groups are located on opposite sides of the plane of the molecule, giving ephedrine a chiral center and two enantiomers (mirror-image isomers)[10].



Fig.1. Molecular Structure of Ephedrine.

Like ephedrine, pseudoephedrine (**fig.2)** has a central carbon atom C that is bonded to an amino group (N), a hydroxyl group (OH), and two methyl groups (CH3). However, in pseudoephedrine, one of the methyl groups is replaced by a hydrogen atom, resulting in a less bulky molecule with a less pronounced chiral center. As a result, pseudoephedrine has only one chiral center and two diastereomers (non-mirror-image isomers)[11].



Fig.2. Molecular Structure of Pseudoephedrine.

1.2 Difference between Ephedrine and Pseudoephedrine

Ephedrine and pseudoephedrine are two similar compounds with slightly different chemical structures and physiological effects.Ephedrine is a naturally occurring alkaloid found in certain plants, including species of the Ephedra genus. It is a sympathomimetic amine that acts as a stimulant and a bronchodilator, meaning it can open up airways in the lungs and improve breathing [12]. Ephedrine can also increase heart rate and blood pressure, and it has been used in the past to treat asthma, nasal congestion, and other respiratory problems [13].

Pseudoephedrine, on the other hand, is a synthetic compound that is chemically similar to ephedrine. It is also a sympathomimetic amine, but it is less potent than ephedrine in its effects on the central nervous system [14]. Pseudoephedrine is commonly used as a decongestant to treat nasal congestion caused by allergies, colds, or the flu. It works by constricting blood vessels in the nasal passages, which reduces swelling and congestion.

One significant difference between ephedrine and pseudoephedrine is their legal status. Ephedrine is a controlled substance in many countries due to its potential for abuse and dependence, while pseudoephedrine is available over-the-counter in most places but is also subject to some regulation due to its use in the illicit manufacture of methamphetamine [15].

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 1447-1455 | ISSN:2251-6727

2. Pharmacology

Ephedrine and pseudoephedrine have similar pharmacological properties, but they differ in their potency and selectivity for various receptors. Both compounds act as indirect sympathomimetic agents by increasing the release of norepinephrine and stimulating both α- and β-adrenergic receptors [16]. Ephedrine has higher affinity for β-adrenergic receptors, whereas pseudoephedrine is more selective for α-adrenergic receptors. Additionally, both compounds have weak direct sympathomimetic effects and can cause release of catecholamines from the adrenal medulla. Both ephedrine and pseudoephedrine also have mild central nervous system stimulant effects [17].

Ephedrine and pseudoephedrine are both sympathomimetic agents that stimulate the sympathetic nervous system. They are used for their bronchodilator and decongestant effects, respectively, but can also have other physiological effects such as increasing heart rate, blood pressure, and metabolic rate [18].

Ephedrine acts on both alpha and beta adrenergic receptors and stimulates the release of norepinephrine from presynaptic nerve terminals, leading to increased sympathetic activity [19]. Its primary use is as a bronchodilator in the treatment of asthma, but it has also been used as a weight loss aid and as a stimulant to increase alertness and energy.Ephedrine is a Schedule V controlled substance in the United States due to its potential for abuse and dependence [20].

Pseudoephedrine is a sympathomimetic agent that acts primarily on alpha adrenergic receptors to produce its decongestant effects. It causes vasoconstriction in nasal blood vessels, reducing swelling and congestion in the nasal passages. Pseudoephedrine is also used to treat urinary incontinence, hypotension, and as a stimulant. Due to its use in the production of the illegal drug methamphetamine, it is a controlled substance in many countries, including the United States [21].

Both ephedrine and pseudoephedrine have potential side effects including palpitations, tachycardia, hypertension, nervousness, insomnia, and gastrointestinal disturbances. They can also cause more serious adverse effects such as arrhythmias, seizures, and stroke, particularly in high doses or with prolonged use. It is important to use these drugs only under the supervision of a healthcare professional and to follow the recommended dosing instructions [22].

3. Clinical Applications

3.1 Treatment of Asthma

Asthma, a chronic respiratory disease, is a prevalent condition worldwide, characterized by persistent inflammation caused by immune cells [23]. The treatment of asthma is complex and multifaceted, but ephedra, with its multiple targets and function pathways, has shown promising results in the management of asthma [24]. The use of ephedra for cough and asthma dates back to ancient times in East Asia, where it was combined with other drugs. Ephedrine, pseudoephedrine, and volatile oils found in ephedra possess anti-asthmatic properties, with ephedrine being the most potent among them [25]. Recent studies have demonstrated that ephedrine, in combination with lignins such as arctiin, arctigenin, descurainoside, and descurainolide B, can produce a bronchodilation effect and alleviate cough and asthma. Furthermore, ephedra has the potential to regulate the immune imbalance in Th1/Th2 and Th17/Treg cells, making it a promising therapeutic option for asthma management in clinical settings [26].

3.2 Treatment of Skin Diseases

Ephedrine and pseudoephedrine are two drugs commonly used for their stimulant and decongestant effects. However, these compounds have also been found to be effective in treating certain skin diseases [27].Ephedrine is a sympathomimetic drug that acts on the sympathetic nervous system. It is commonly used as a decongestant and bronchodilator, and has been used in traditional Chinese medicine for thousands of years to treat respiratory conditions. In recent years, ephedrine has also been found to be effective in the treatment of certain skin diseases, such as atopic dermatitis, psoriasis, and vitiligo [28].

Atopic dermatitis, also known as eczema, is a chronic skin condition characterized by dry, itchy, and inflamed skin. It is believed to be caused by an overactive immune system, which leads to inflammation and damage to the skin barrier [29]. Ephedrine has been found to have anti-inflammatory effects, which can help to reduce the symptoms of atopic dermatitis [30]. In a study published in the Journal of Investigative

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 1447-1455 | ISSN:2251-6727

Dermatology, researchers found that ephedrine can inhibit the production of inflammatory cytokines in the skin, which can help to reduce inflammation and improve the skin barrier function [31].

Psoriasis is another chronic skin condition that is characterized by red, scaly patches on the skin. It is caused by an overproduction of skin cells, which leads to the formation of thick, scaly patches [32]. Ephedrine has been found to have antiproliferative effects, which can help to reduce the production of skin cells in patients with psoriasis [33]. In a study published in the Journal of Dermatological Science, researchers found that ephedrine can inhibit the growth of keratinocytes, which are the cells that make up the majority of the skin [34]

Vitiligo is a skin condition that is characterized by the loss of pigment in the skin. It is believed to be caused by an autoimmune response, which leads to the destruction of melanocytes, the cells that produce pigment in the skin [35]. Ephedrine has been found to have immunomodulatory effects, which can help to regulate the immune system and reduce the autoimmune response [36]. In a study published in the Journal of Investigative Dermatology, researchers found that ephedrine can inhibit the production of antibodies that are involved in the destruction of melanocytes [37].

Pseudoephedrine is a sympathomimetic drug that is commonly used as a decongestant. It works by constricting blood vessels in the nasal passages, which reduces swelling and congestion. Pseudoephedrine has also been found to be effective in the treatment of certain skin diseases, such as urticaria and angioedema [38].

Urticaria, also known as hives, is a skin condition that is characterized by itchy, red, and raised welts on the skin. It is caused by an allergic reaction, which leads to the release of histamine and other inflammatory mediators [39]. Pseudoephedrine has been found to have antihistamine effects, which can help to reduce the symptoms of urticaria [40].

Angioedema is a condition that is similar to urticaria, but it affects deeper layers of the skin and can cause swelling in the face, lips, tongue, and throat. It is also caused by an allergic reaction, and can be life-threatening if it affect [41].

3.3 Treatment Gynecological Diseases

According to traditional Chinese medicine, gynecological issues are often attributed to yang deficiency and cold coagulation. Ephedra has been found to have a regulating effect on yang, which not only warms the meridians but also invigorates qi and dispels cold [42]. Interestingly, Ephedra has also been utilized in California as a treatment for female dysmenorrhea and premenstrual syndrome, among other herbs [43]. In Palestine, Ephedra is the most commonly used plant in breast cancer treatment [44]. Furthermore, researchers have conducted XTT analysis to evaluate the cytotoxicity of Ephedra on ovarian cancer cell lines (A2780 and A2780CisR) and noncancerous kidney cells (HEK-293). The results showed that Ephedra treatment reduced the sensitivity of ovarian cancer cells to cisplatin and their cytotoxicity [45].

3.4 Used as analgesic

Ephedra's unique analgesic effect may be attributed to its combination of pseudoephedrine and polysaccharides, which work together to relax smooth muscle and relieve blood stasis. Research conducted by Schachtel et al. on 640 patients with upper respiratory tract infection found that the combination of acetylsalicylic acid (ASA) and pseudoephedrine (PSE) produced good analgesic effects with good tolerance [26]. In addition, oral administration of pseudoephedrine in adults was found to reduce pain and trauma in the middle ear during aviation flight [46]. Although the analgesic effect of Ephedra is primarily attributed to pseudoephedrine and polysaccharides, the exact mechanism through which it produces its analgesic effect is still not fully understood [47].

3.5 Used as weight loss medicine

Ephedrine and pseudoephedrine are both sympathomimetic drugs that have been used as weight loss aids due to their ability to increase metabolic rate and decrease appetite [48].The mechanism of action of ephedrine and pseudoephedrine involves their ability to stimulate the sympathetic nervous system, which activates the release of the neurotransmitter norepinephrine from nerve endings [49]. Norepinephrine then binds to and activates adrenergic receptors, leading to increased lipolysis (breakdown of fat) and thermogenesis (heat production) in adipose tissue. This increases the body's energy expenditure and

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 1447-1455 | ISSN:2251-6727

can contribute to weight loss [50].Additionally, ephedrine and pseudoephedrine can also decrease appetite by acting on the central nervous system. They increase the release of the neurotransmitter dopamine, which can affect the reward center in the brain and decrease feelings of hunger and cravings for food [51].

4. Adverse Effects

Ephedrine and pseudoephedrine are both sympathomimetic agents that act on the central nervous system to increase heart rate and blood pressure, among other effects. While these drugs can be effective for treating nasal congestion and asthma, they can also cause a range of adverse effects, including:

4.1 Cardiovascular Effects

Drugs can cause an increase in heart rate, blood pressure, and arrhythmias (irregular heartbeats). In some cases, this can lead to serious cardiovascular events, such as heart attack or stroke [52].*Increased heart rate:* Both ephedrine and pseudoephedrine can increase heart rate. This can be particularly dangerous for people with pre-existing heart conditions, such as *arrhythmias* [53].*Elevated blood pressure:* These drugs can also cause an increase in blood pressure. This can be particularly concerning for people with hypertension, as it can exacerbate the condition [54].*Constriction of blood vessels:* Both ephedrine and pseudoephedrine can cause constriction of blood vessels, which can reduce blood flow to the heart and other vital organs. This can be particularly dangerous for people with pre-existing cardiovascular disease [55].*Increased risk of heart attack and stroke:* In rare cases, these drugs have been associated with an increased risk of heart attack and stroke. This risk is particularly elevated in people with pre-existing cardiovascular disease or risk factors for these conditions.

4.2 Central nervous system effects:

Ephedrine and pseudoephedrine can cause nervousness, anxiety, insomnia, and restlessness. In high doses, they may even cause seizures or hallucinations.

Anxiety: These drugs can cause an increase in the release of the stress hormone cortisol, which can cause anxiety and nervousness.***Insomnia****:* Ephedrine and pseudoephedrine can stimulate the CNS and interfere with sleep, leading to insomnia [56].*Headaches:* The vasoconstrictive effects of ephedrine and pseudoephedrine can cause headaches [57].***Tremors****:* The stimulatory effects of these drugs on the CNS can lead to tremors, particularly in the hands and fingers [58].*Seizures:* In rare cases, ephedrine and pseudoephedrine can cause seizures, particularly in individuals with a history of seizure disorders [59].

4.3 Gastrointestinal effects:

Nausea and vomiting: Ephedrine and pseudoephedrine can cause irritation of the stomach lining, leading to nausea and vomiting. This can occur particularly when the drugs are taken on an empty stomach [60]. ***Diarrhea***: Ephedrine and pseudoephedrine can cause increased motility of the intestines, leading to diarrhea. This is more likely to occur with higher doses of the drugs [61].***Abdominal pain:*** Ephedrine and pseudoephedrine can cause irritation of the digestive tract, leading to abdominal pain.***Gastrointestinal bleeding:*** Rarely, ephedrine and pseudoephedrine can cause gastrointestinal bleeding, particularly if taken in large doses or over an extended period of time [62].*Ulceration:* Chronic use of ephedrine and pseudoephedrine can lead to ulceration of the stomach lining, which can cause pain and bleeding [63].

4.4 UrinaryRetention:

Pseudoephedrine can cause urinary retention, which can lead to bladder problems and urinary tract infections.Urinary retention is a condition where the bladder is unable to empty completely, leading to a buildup of urine in the bladder [64]. This can be caused by various factors, including prostate enlargement, neurological disorders, and certain medications such as ephedrine and pseudoephedrine.These drugs have been reported to cause urinary retention in susceptible individuals, especially those with pre-existing bladder outlet obstruction or neurogenic bladder. They can cause smooth muscle contraction in the bladder neck and prostate, leading to an increase in resistance to urine flow and ultimately to urinary retention.In addition, ephedrine and pseudoephedrine are also known to cause dehydration, which can further exacerbate the problem of urinary retention [65].

4.5 Allergic Reaction:

While skin allergies are not typically listed as a common side effect of these medications, some people may experience an allergic reaction that can manifest in skin symptoms.The most common skin reaction

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 1447-1455 | ISSN:2251-6727

associated with ephedrine and pseudoephedrine is hives, which are raised, itchy, and red patches on the skin [66]. Other skin symptoms that may occur as a result of an allergic reaction to these medications include rash, swelling, and itching.

4.6 Drug interactions:

Ephedrine and pseudoephedrine can interact with other drugs, including antidepressants and blood pressure medications, leading to serious side effects.***MAO inhibitors****:* Taking ephedrine or pseudoephedrine with a monoamine oxidase (MAO) inhibitor can cause a dangerous increase in blood pressure [67]. *Beta blockers:* Ephedrine and pseudoephedrine can counteract the effects of beta blockers, which are used to treat high blood pressure and other cardiovascular conditions [68].***Antidepressants****:* Certain types of antidepressants, such as tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs), can interact with ephedrine and pseudoephedrine and increase the risk of side effects [69].*Other stimulants:* Combining ephedrine or pseudoephedrine with other stimulants, such as caffeine or amphetamines, can increase the risk of cardiovascular side effects, such as increased heart rate and blood pressure [70].***Blood thinners:*** Ephedrine and pseudoephedrine can interact with blood thinners, such as warfarin, and increase the risk of bleeding [71].

5 Conclusion

Ephedrine and pseudoephedrine are two related compounds with a long history of use in medicine. They have a range of clinical applications, including as decongestants, bronchodilators, and for the treatment of hypotension and shock. However, their use is also associated with a range of adverse effects, especially when used in high doses or for extended periods. Therefore, their use should be carefully monitored and their potential benefits and risks should be carefully weighed before use.

In conclusion, Ephedrine and Pseudoephedrine are two closely related compounds that have been used for a variety of medical purposes, including as a bronchodilator, decongestant, and appetite suppressant. While they share many pharmacological properties, they differ in their selectivity and potency for different adrenergic receptors.

Ephedrine is a non-selective agonist of α- and β-adrenergic receptors, and its effects on the cardiovascular and respiratory systems make it a useful tool for treating asthma, hypotension, and shock. Pseudoephedrine, on the other hand, has greater selectivity for α-adrenergic receptors, and its vasoconstrictive effects make it a popular decongestant.

While both drugs have therapeutic uses, they can also be abused and are sometimes used as a recreational drug. The potential for abuse and addiction has led to the regulation of ephedrine and pseudoephedrine in many countries, including the United States.

Despite their long history of use, there is still ongoing research into the pharmacology and clinical applications of ephedrine and pseudoephedrine. For example, recent studies have looked at the effects of ephedrine on cognitive performance and sports performance, and there is interest in the potential use of pseudoephedrine for the treatment of obesity.

Overall, while ephedrine and pseudoephedrine have their benefits, they should be used with caution and under the guidance of a healthcare professional. Their potential for abuse and side effects, particularly at high doses or with prolonged use, should not be overlooked. As such, continued research is necessary to fully understand their pharmacology and clinical applications, and to ensure their safe and effective use.

References

1. Gad, M. Z., Azab, S. S., Khattab, A. R., &Farag, M. A. (2021). Over a century since ephedrine discovery: an updated revisit to its pharmacological aspects, functionality and toxicity in comparison to its herbal extracts. Food & Function, 12(20), 9563-9582.
2. Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008). Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis international, 19, 733-759.
3. Iqbal, A., Khera, R. A., Hanif, M. A., Ayub, M. A., & Zafar, M. N. (2020). Ma-Huang. In Medicinal Plants of South Asia (pp. 479-494). Elsevier.
4. Gad, M. Z., Azab, S. S., Khattab, A. R., &Farag, M. A. (2021). Over a century since ephedrine discovery: an updated revisit to its pharmacological aspects, functionality and

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 1447-1455 | ISSN:2251-6727

toxicity in comparison to its herbal extracts. Food & Function, 12(20), 9563-9582.

5. Chen, K. K., & Kao, C. H. (1926). Ephedrine and pseudoephedrine, their isolation, constitution, isomerism, properties, derivatives and synthesis.(With a bibliography). The Journal of the American Pharmaceutical Association (1912), 15(8), 625-639.
6. Avois, L., Robinson, N., Saudan, C., Baume, N., Mangin, P., &Saugy, M. (2006). Central nervous system stimulants and sport practice. British journal of sports medicine, 40(Suppl 1), i16.
7. Taylor, J. (2015). The stimulants of Prohibition: Illegality and new synthetic drugs. Territory, Politics, Governance, 3(4), 407-427.
8. Soni, M. G., Carabin, I. G., Griffiths, J. C., & Burdock, G. A. (2004). Safety of ephedra: lessons learned. Toxicology letters, 150(1), 97-110.
9. Ma, G., Bavadekar, S. A., Davis, Y. M., Lalchandani, S. G., Nagmani, R., Schaneberg, B. T., … & Feller, D. R. (2007). Pharmacological effects of ephedrine alkaloids on human α1-and α2-adrenergic receptor subtypes. Journal of Pharmacology and Experimental Therapeutics, 322(1), 214-221.
10. Gaddum, J. H. (1938). Ephedrine. British Medical Journal, 1(4030), 713.
11. Butz, P., Kroemer, R. T., Macleod, N. A., & Simons, J. P. (2001). Conformational preferences of neurotransmitters: ephedrine and its diastereoisomer, pseudoephedrine. The Journal of Physical Chemistry A, 105(3), 544-551.
12. El-Sakka, M. A. (2010). Phytochemistry (3) alkaloids. Al Azhar University, Faculty of Pharmacy, Department of Pharmacognosy: Cairo, Egypt.
13. Drew, C. D., Knight, G. T., Hughes, D. T., & Bush, M. (1978). Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man. British journal of clinical pharmacology, 6(3), 221-225.
14. Costa, V. M., Grando, L. G. R., Milandri, E., Nardi, J., Teixeira, P., Mladěnka, P., … & OEMONOM. (2022). Natural Sympathomimetic Drugs: From Pharmacology to Toxicology. Biomolecules, 12(12), 1793.
15. Burks, S. (2012). The regulation of ephedrine and pseudoephedrine to reduce the hazards of methamphetamine labs and availability of methamphetamine.
16. Biaggioni, I., & Robertson, D. (2009). Adrenoceptor agonists & sympathomimetic drugs. Basic & clinical pharmacology, 12, 129-149.
17. Westfall, T. C., & Westfall, D. P. (2006). Adrenergic agonists and antagonists. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed. Edited by Brunton LL, Lazo JS, Parker KL. New York, McGraw-Hill, 237-315.
18. Westfall, T. C., & Westfall, D. P. (2006). Adrenergic agonists and antagonists. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed. Edited by Brunton LL, Lazo JS, Parker KL. New York, McGraw-Hill, 237-315.
19. Adams, H. R. (1995). Adrenergic agonists and antagonists. Veterinary pharmacology and therapeutics, 7, 87-113.
20. Palamar, J. (2011). How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy. Health Policy, 99(1), 1-9.
21. Stimulants, A. T. (2013). Amphetamine. Addictions: A Comprehensive Guidebook, 174.
22. Gad, M. Z., Azab, S. S., Khattab, A. R., &Farag, M. A. (2021). Over a century since ephedrine discovery: an updated revisit to its pharmacological aspects, functionality and toxicity in comparison to its herbal extracts. Food & Function, 12(20), 9563-9582.
23. Holtzman, M. J., Byers, D. E., Alexander-Brett, J., & Wang, X. (2014). The role of airway epithelial cells and innate immune cells in chronic respiratory disease. Nature Reviews Immunology, 14(10), 686-698.
24. Wang, Y., Chen, Y. J., Xiang, C., Jiang, G. W., Xu, Y. D., Yin, L. M., … & Yang, Y. Q. (2020). Discovery of potential asthma targets based on the clinical efficacy of Traditional Chinese Medicine formulas. Journal of Ethnopharmacology, 252, 112635.
25. Zheng, Q., Mu, X., Pan, S., Luan, R., & Zhao, P. (2023). Ephedraeherba: A comprehensive review of its traditional uses, phytochemistry,

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 1447-1455 | ISSN:2251-6727

pharmacology, and toxicology. Journal of Ethnopharmacology, 116153.

26. Tang, S., Ren, J., Kong, L., Yan, G., Liu, C., Han, Y., … & Wang, X. J. (2023). EphedraeHerba: A Review of Its Phytochemistry, Pharmacology, Clinical Application, and Alkaloid Toxicity. Molecules, 28(2), 663.
27. Głowacka, K., &Wiela-Hojeńska, A. (2021). Pseudoephedrine—benefits and risks. International Journal of Molecular Sciences, 22(10), 5146.
28. Shenefelt, P. D. (2012). Herbal treatment for dermatologic disorders.
29. Leung, D. Y. (2013). New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergology international, 62(2), 151-161.
30. Chen, X., Lin, J., Liang, Q., Chen, X., & Wu, Z. (2020). Pseudoephedrine alleviates atopic dermatitis-like inflammatory responses in vivo and in vitro. Life sciences, 258, 118139.
31. Wu, S., Pang, Y., He, Y., Zhang, X., Peng, L., Guo, J., & Zeng, J. (2021). A comprehensive review of natural products against atopic dermatitis: Flavonoids, alkaloids, terpenes, glycosides and other compounds. Biomedicine & Pharmacotherapy, 140, 111741.
32. Shah, N. V., Maheshwari, R. A., Sailor, G. U., Aundhia, C. J., Chauhan, S. P., &Javia, A. R. (2010). A REVIEW ON ETIOLOGY, TYPES AND TREATMENT OF PSORIASIS. Pharmacologyonline, 1, 159-179.
33. Parker, S., Zhang, C. S., Yu, J. J., Lu, C., Zhang, A. L., &Xue, C. C. (2017). Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: a systematic review. Journal of Dermatological Treatment, 28(1), 21-31.
34. Herman, A., & Herman, A. P. (2012). Caffeine's mechanisms of action and its cosmetic use. Skin pharmacology and physiology, 26(1), 8-14.
35. Xie, H., Zhou, F., Liu, L., Zhu, G., Li, Q., Li, C., & Gao, T. (2016). Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity?. Journal of Dermatological Science, 81(1), 3-9.
36. Lee, S. H., Lee, H., & Park, R. (2023). Systemic Immune Modulation Induced by Ephedrine in Obese-Diabetes (db/db) Mice. Current Issues in Molecular Biology, 45(12), 10097-10108.
37. Issa, R. A., Afifi, F. U., &Amro, B. (2005). Studying the skin whitenning effect of Arbutus andrachne L. extract (Doctoral dissertation, University of Jordan).
38. Cingi, C., Bayar Muluk, N., Mitsias, D. I., Papadopoulos, N. G., Klimek, L., Laulajainen-Hongisto, A., … &Scadding, G. K. (2021). The nose as a route for therapy: part 1. Pharmacotherapy. Frontiers in allergy, 2, 638136.
39. Arul Selvan, M. (2020). Comparison of Efficacy of Various Treatment Modalities in Patients with Chronic Spontaneous Urticaria (Doctoral dissertation, Madras Medical College, Chennai).
40. JurakićTončić, R., Lipozenčić, J., &Marinović, B. (2009). Treatment of chronic urticaria. ActaDermatovenerologicaCroatica, 17(4), 0-0.
41. Kaplan, A. P. (2008). Angioedema. World Allergy Organization Journal, 1(6), 103-113.
42. Lu, C. (2015). Clinical Practice Guided by the Supporting-Yang Theory. In HANDBOOK OF TRADITIONAL CHINESE MEDICINE (pp. 851-868).
43. Dasgupta, A. (2003). Review of abnormal laboratory test results and toxic effects due to use of herbal medicines. American journal of clinical pathology, 120(1), 127-137.
44. Jaradat, N. A., Al-Ramahi, R., Zaid, A. N., Ayesh, O. I., & Eid, A. M. (2016). Ethnopharmacological survey of herbal remedies used for treatment of various types of cancer and their methods of preparations in the West Bank-Palestine. BMC complementary and alternative medicine, 16(1), 1-12.
45. González-Juárez, D. E., Escobedo-Moratilla, A., Flores, J., Hidalgo-Figueroa, S., Martínez-Tagüeña, N., Morales-Jiménez, J., … & Bautista, E. (2020). A review of the Ephedra genus: distribution, ecology, ethnobotany, phytochemistry and pharmacological properties. Molecules, 25(14), 3283.
46. Buchanan, B. J., Hoagland, J., & Fischer, P. R. (1999). Pseudoephedrine and air travel–associated ear pain in children. Archives of pediatrics& adolescent medicine, 153(5), 466-468.
47. El-Sakka, M. A. (2010). Phytochemistry (3) alkaloids. Al Azhar University, Faculty of

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 1447-1455 | ISSN:2251-6727

Pharmacy, Department of Pharmacognosy: Cairo, Egypt.
48. Głowacka, K., &Wiela-Hojeńska, A. (2021). Pseudoephedrine—benefits and risks. International Journal of Molecular Sciences, 22(10), 5146.
49. Kleinz, M. J., & Spence, I. (2008). The pharmacology of the autonomic nervous system. Small animal clinical pharmacology. Saunders Elsevier, USA, Philadelphia, 59-82.
50. Braun, K., Oeckl, J., Westermeier, J., Li, Y., &Klingenspor, M. (2018). Non-adrenergic control of lipolysis and thermogenesis in adipose tissues. Journal of Experimental Biology, 221(Suppl_1), jeb165381.
51. Komsta, Ł., &Wicha-Komsta, K. (2018). Biological Background of Designer Drugs. In Chromatographic Techniques in the Forensic Analysis of Designer Drugs (pp. 39-66). CRC Press.
52. White, W. B. (2001). Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood pressure monitoring, 6(2), 63-72.
53. Schachter, M. (2010). Drugs that affect autonomic functions or the extrapyramidal system. Side Effects of Drugs Annual, 32, 281-294.
54. Brown, M. J., Cruickshank, J. K., Dominiczak, A. F., MacGregor, G. A., Poulter, N. R., Russell, G. I., … & Williams, B. (2003). Better blood pressure control: how to combine drugs. Journal of human hypertension, 17(2), 81-86.
55. Abdulrahman, A., & Pharm, B. (2019). A study of α-Adrenoceptor agonists on porcine nasal and extra-nasal vasculature: insight into decongestant activity (Doctoral dissertation, University of Nottingham).
56. Nakaki, T. (2014). Drugs that affect autonomic functions or the extrapyramidal system. In Side Effects of Drugs Annual (Vol. 36, pp. 179-202). Elsevier.
57. Laccourreye, O., Werner, A., Giroud, J. P., Couloigner, V., Bonfils, P., &Bondon-Guitton, E. (2015). Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants. European Annals of Otorhinolaryngology, Head and Neck Diseases, 132(1), 31-34.
58. Elias, W. J., & Shah, B. B. (2014). Tremor. Jama, 311(9), 948-954.
59. Haller, C. A., Meier, K. H., & Olson, K. R. (2005). Seizures reported in association with use of dietary supplements. Clinical toxicology, 43(1), 23-30.
60. Blenkinsopp, A., Paxton, P., & Blenkinsopp, J. (2007). Symptoms in the pharmacy. John Wiley & Sons, Limited.
61. Salem, C. B., Hmouda, H., &Bouraoui, K. (2009). Drug-induced hypokalaemia. Current drug safety, 4(1), 55-61.
62. Indra, I., &Adhiany, E. (2020). Medicines Used in Emergency. Britain International of Exact Sciences (BIoEx) Journal, 2(2), 510-521.
63. Rathor, S., Bhattacharjee, C., Jain, A., & Deb, L. International Journal of Pharmacology and Clinical Research (IJPCR). Allergy, 2, 3.
64. Selius, B. A., &Subedi, R. (2008). Urinary retention in adults: diagnosis and initial management. American family physician, 77(5), 643-650.
65. Curtis, L. A., Dolan, T. S., &Cespedes, R. D. (2001). Acute urinary retention and urinary incontinence. Emergency medicine clinics of North America, 19(3), 591-620.
66. Newby, D., & Rutter, P. (2007). Community pharmacy: symptoms, diagnosis and treatment. Elsevier Health Sciences.
67. Stahl, S. M., &Felker, A. (2008). Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS spectrums, 13(10), 855-871.
68. Akay, S., &Ozdemir, M. (2008). Acute coronary syndrome presenting after pseudoephedrine use and regression with beta-blocker therapy. Canadian Journal of Cardiology, 24(11), e86-e88.
69. Saraghi, M., Golden, L. R., &Hersh, E. V. (2017). Anesthetic considerations for patients on antidepressant therapy—part I. Anesthesia progress, 64(4), 253-261.
70. Avois, L., Robinson, N., Saudan, C., Baume, N., Mangin, P., &Saugy, M. (2006). Central nervous system stimulants and sport practice. British journal of sports medicine, 40(Suppl 1), i16.
71. Cupp, M. J. (1999). Herbal remedies: adverse effects and drug interactions. American family physician, 59(5), 1239-1244.